Thymosin Alpha-1 (Thymalfasin): Evidence, Approvals, and the Weight-Loss Myth

Thymosin alpha-1 (Tα1, generic name thymalfasin, brand Zadaxin) is a 28-amino-acid immune-modulating peptide — and it is one of the more interesting entries in the peptide world because, unlike most “research peptides,” it has a real, if mixed, clinical track record. It is approved or registered in roughly 35 countries for chronic hepatitis B and C and as immune support, and it has been studied in sepsis and COVID-19. What it is not: it is not approved by the US FDA for any indication, and it is not a weight-loss peptide — no human trial reports weight loss as an outcome, and there is no mechanistic reason to expect one. In the United States it is sold grey-market as a “research peptide” for vague “immune” and “longevity” benefits that go well beyond what the evidence supports. This is a balanced evidence review — what Tα1 actually is, where it is genuinely approved and what the trials show, why it is unapproved in the US, and why “approved abroad” does not mean “proven for the biohacker claims.” It is not a dosing or how-to-buy guide.

The honest summary

• It is a real immune-modulating peptide. Thymosin alpha-1 is a 28-amino-acid fragment originally isolated from thymic tissue. It nudges the immune system — promoting T-cell maturation, restoring depleted lymphocytes, and modulating inflammatory signaling^[1][2].
• It is genuinely approved — just not in the US. Thymalfasin (Zadaxin) is approved or registered in roughly 35 countries for chronic hepatitis B and C and as immune support and a vaccine adjuvant^[2]. It is not FDA-approved in the United States and is not listed as an approved drug in DailyMed.
• The clinical evidence is mixed. Some hepatitis and COVID-19 studies are encouraging^[3][4], while the largest, most rigorous sepsis trial was flatly negative^[6]. “Approved abroad” is not the same as “definitively proven.”
• It is NOT a weight-loss peptide. No human trial reports weight loss as an outcome for thymosin alpha-1, and its biology — immune modulation, not appetite or metabolism — offers no plausible fat-loss pathway. Any weight-loss marketing is unsupported.
• In the US it is a grey-market product. Sold as a “research peptide” labeled not for human consumption, often for unproven “immune” and “anti-aging” uses. Purity, sterility, and dose of US grey-market vials are not verified by any agency.
• It is not in the same category as obesity drugs. If weight loss is the goal, the evidence sits with FDA-approved medications like semaglutide (−14.9%) and tirzepatide (up to −20.9%) in large Phase-3 trials^[8][9] — not with an immune peptide.

What thymosin alpha-1 actually is

Thymosin alpha-1 is a small peptide (28 amino acids) first purified decades ago from thymosin fraction 5, an extract of the thymus — the gland that trains the immune system’s T cells. The synthetic version used clinically is called thymalfasin and sold under the brand Zadaxin. Its job is immunomodulation: it helps immature T cells mature, supports the activity of natural killer cells and dendritic cells, and can help restore lymphocyte counts that have been depleted by infection or illness^[1][2]. Because the immune system weakens with age, Tα1 has also been studied in the context of immunosenescence and aging^[1]. None of this biology touches appetite, satiety, fat storage, or energy expenditure — the pathways a weight-loss drug acts on.

Where it is genuinely approved — and the evidence behind it

This is what sets thymosin alpha-1 apart from peptides like BPC-157 or TB-500: it is an actually approved drug in much of the world. Thymalfasin is approved or registered in roughly 35 countries for chronic hepatitis B and C, and is used as an immune support agent and a vaccine adjuvant^[2]. Its longest-standing evidence base is in viral hepatitis: for example, a study of entecavir plus thymosin alpha-1 versus entecavir alone in chronic hepatitis B reported improvements in virologic and immune endpoints with the combination^[3]. The literature here is real, though it is dominated by combination regimens and trials run largely in Asia, and the size and quality of individual studies vary.

During the pandemic, Tα1 was studied in COVID-19 on the logic that severe disease is marked by lymphocyte depletion — exactly the deficit Tα1 is thought to correct. An early observational cohort of severe COVID-19 patients reported that thymosin alpha-1 was associated with reduced mortality and restoration of lymphocyte counts^[4]. But subsequent pooled analyses were more cautious: a systematic review and meta-analysis of Tα1 in adult COVID-19 patients found the overall clinical evidence mixed and limited by study quality, stopping short of a confident benefit claim^[5]. That gap — promising single cohorts, equivocal pooled evidence — is a recurring theme with this peptide.

The sepsis trial: a clean negative result

The most important data point for honest framing is the TESTS trial — a multicentre, double-blind, placebo-controlled Phase-3 randomized trial of thymosin alpha-1 in 1,106 adults with sepsis, published in The BMJ in 2025. Its result was unambiguous and disappointing for Tα1: 28-day all-cause mortality was 23.4% with thymosin alpha-1 versus 24.1% with placebo (hazard ratio 0.99, 95% CI 0.77–1.27, P=0.93), and no secondary or safety outcome differed significantly. The authors concluded there was no clear evidence that thymosin alpha-1 decreases sepsis mortality^[6]. A 2025 systematic review and meta-analysis of Tα1 RCTs in sepsis reached a similarly hedged position, noting that earlier positive signals came largely from smaller, lower-quality Chinese trials^[7]. When a peptide finally gets a large, rigorous trial and the result is null, that is exactly the kind of evidence the “immune-boosting” marketing leaves out.

US status: not FDA-approved, sold grey-market

In the United States, thymosin alpha-1 is not FDA-approved for any indication. It is not an approved drug product and is not listed in DailyMed. Despite its approval status abroad, in the US it is sold the way other research peptides are — online, often labeled “for research use only, not for human consumption,” and marketed for vague “immune support,” “longevity,” and “recovery” benefits, sometimes including weight or body-composition claims. A 2024 review of thymosin alpha-1 in human clinical trials catalogs where the human evidence actually exists (hepatitis, immune restoration, adjunctive infection settings) and where it does not^[2] — and weight loss is nowhere on that list. The practical reality of a US grey-market vial is that no agency has verified its identity, purity, sterility, or dose.

Why it is not a weight-loss peptide

Thymosin alpha-1’s entire mechanism is immune: T-cell maturation, lymphocyte restoration, and modulation of inflammatory signaling^[1][2]. None of that is a weight-loss pathway. There is no published human trial in which weight loss is an outcome of thymosin alpha-1, and there is no credible mechanistic route by which an immune-modulating peptide would drive fat loss in healthy people. When it appears in “weight-loss peptide” stacks, it is being borrowed for a job it was never studied for. For weight loss, the honest comparison is with drugs that have actually been tested for it: semaglutide (Wegovy) produced a mean −14.9% body-weight change at 68 weeks in the STEP-1 Phase-3 trial^[8], and tirzepatide (Zepbound) up to −20.9% at 72 weeks in SURMOUNT-1^[9]. Thymosin alpha-1 has nothing in that category.

For the wider picture, see our hub review of peptides for weight loss, which sorts FDA-approved peptide drugs from compounded versions and unapproved research peptides, the companion debunker on non-GLP-1 peptides marketed for fat loss, and our forthcoming A-to-Z peptide evidence guide.

Bottom line

Thymosin alpha-1 is a genuine immune-modulating peptide with a real, if mixed, clinical record: approved or registered in roughly 35 countries for chronic hepatitis B and C and immune support, with encouraging data in some hepatitis and COVID-19 settings^[3][4] but a clearly negative Phase-3 sepsis trial^[6]. In the United States it is not FDA-approved for anything and is sold grey-market as a “research peptide” for claims the evidence does not support. Most importantly for this site: it is not a weight-loss peptide — no human trial measures weight loss, and its immune biology offers no fat-loss pathway. “Approved abroad” is a real distinction, but it is not a license for the longevity-and-weight-loss claims attached to it here. If weight loss is your goal, the evidence points to FDA-approved medications with published human trials^[8][9].

This article is educational and is not medical advice. Every claim above is sourced to peer-reviewed literature indexed in PubMed or to the regulatory status of the compound, verified against the live PubMed database before publication. Citations 1 through 7 cover thymosin alpha-1 biology, hepatitis, COVID-19, and sepsis evidence; citations 8 and 9 are human Phase-3 randomized trials of FDA-approved obesity drugs, cited for contrast. Discuss any treatment with a licensed prescriber.